HÀ NỘI — Việt Nam has signed COVID-19 vaccine technology transfer contracts with Russia, the US, and Japan, said Nguyễn Ngô Quang, Deputy Director of the Health Ministry's Department for Science, Technology and Training.
According to the official, one of the three was sealed between two Vietnamese companies – the Company for Vaccine and Biological Production No.1 (VABIOTECH) and the International Progressive Joint Stock Company (AIC) – and Japanese pharmaceutical firm Shionogi. VABIOTECH, a State-owned enterprise under the Ministry of Health, is one of the leading units in the field of research, manufacture and sale of vaccines and biological products for human use in the country.
Their deal targeted the transfer of the Recombinant SARS-CoV-2 Spike Protein, a baculovirus expression vector system, with the parties signing a confidentiality agreement to access vaccine and technology records.
Regarding the technology transfer project between the AIC and Shionogi, the Ministry of Health has signed a cooperation agreement and is preparing a plan to conduct the third phase of clinical trials in Việt Nam (via the National Institute of Hygiene and Epidemiology) and procedures for technology transfer (via VABIOTECH). It is expected that the vaccine will be completed and on the market in June 2022.
The second contract involving the Russian Sputnik V vaccine was inked between VABIOTECH, DS-Bio, and the Russian Direct Investment Fund, with the Vietnamese side in charge of packaging the vaccine tubes from the semi-finished products.
VABIOTECH has sent its sample tubes to Russia for quality checks. After related tests finish on August 10 as scheduled, Sputnik-V vaccine tubes would be produced under the contract at a volume of 5 million doses per month. It would start with 500,000 doses in August and later scale up to 100 million doses per year.
For technology transfer project with US partners, the Ministry of Health has sent a group of experts to coordinate with the World Health Organization (WHO) to support relevant units in completing dossiers for clinical trials according to a shortened process, with the research expected to start on August 1 and end in late December.
Vingroup controlled-VinBiocare is reported to be in negotiations with Arcturus Therapeutics, maker of a mRNA COVID-19, for the phase 3 trials in Việt Nam and subsequent production.
The transfer and the building of a vaccine factory in Việt Nam will be completed in June 2022. — VNS
- Growing Chinese investment in Việt Nam: time to worry?
- JICA implements sustainable development projects in Quảng Nam
- TPBank first bank to apply blockchain in money transfer
- U.S.-China trade deal signing could be delayed to December; London a possible venue - source
- China and France sign deals worth US$15 billion during Macron's visit
- Japanese Trade Minister Weighs Up Future of Proposed Energy Bridge to Russia
- Russia, India Agree to Ink Arms Deals in Own Currencies to Skirt US Sanctions – Report
- Russia moves toward creation of an independent internet
- Businesses erring in ignoring quantum technology: PwC
- Transfer watch: City sign Laporte for club-record fee; Gunner Giroud joins Chelsea
- Rocket Report: Russia plans a mini Falcon 9; Shotwell takes aim at Blue
- Will Rajnath's Russia visit help India get defence deals?
- Chairman's Statement of 26th ASEAN Summit issued
- ASEAN meetings end on high note
- Logistic booms with million-dollar deals, foreign firms look to spread
- Johnson Electric reports results for the half year ended 30 September 2019
- Son bounces back with a brace as Tottenham thrash Red Star again
- Textile-garment exports seen at $35b this year
- Saigon Hi-tech Park to hold int’l conference on blockchain
- Bullet trains and more: Modi, Abe's big plans
Việt Nam signs vaccine technology transfer contracts with Japan, US and Russia have 610 words, post on vietnamnews.vn at July 28, 2021. This is cached page on Talk Vietnam. If you want remove this page, please contact us.